Varegacestat, an investigational gamma secretase inhibitor (GSI), delivered clinically meaningful improvements in efficacy ...
Erdafitinib showed a predictable toxicity profile and early efficacy in IDH–wild-type glioma with FGFR-TACC fusions. The recommended phase 2 dose was 8 mg daily, with one grade 3 central serous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback